natgillin/translations-raw huggingface dataset:
an analysis of any structural aspects of the relevant instruments issued by an issuer, which for structured finance instruments shall include an analysis of the inherent operational and counterparty risk of the structured finance instrument;
analiza vseh strukturnih vidikov zadevnih instrumentov, ki jih je izdal izdajatelj, pri čemer analiza strukturiranih finančnih instrumentov vključuje analizo z njimi povezanega operativnega tveganja in tveganja nasprotne stranke;
an analysis of the relevant market(s), including the degree of volume and liquidity of those markets;
analiza zadevnih trgov, vključno z njihovim obsegom in stopnjo likvidnosti;
a sovereign analysis, including the extent of explicit and contingent liabilities and the size of foreign exchange reserves compared to foreign exchange liabilities;
analiza držav, vključno z obsegom eksplicitnih in pogojnih obveznosti ter višino deviznih rezerv v primerjavi z deviznimi obveznostmi;
an analysis of governance risk relating to the issuer, including frauds, conduct fines, litigation, financial restatements, exceptional items, management turnover, borrower concentration and audit quality;
analiza tveganja v zvezi z upravljanjem, povezanega z izdajateljem, vključno z goljufijami, denarnimi kaznimi zaradi ravnanja, pravnimi spori, preračuni računovodskih izkazov, izrednimi postavkami, fluktuacijo vodstvenega osebja, koncentracijo posojilojemalcev in kakovostjo revizij;
securities-related research on the issuer or market sector;
raziskave glede vrednostnih papirjev v zvezi z izdajateljem ali tržnim sektorjem;
where relevant, an analysis of the credit ratings or rating outlook given to the issuer of an instrument by a credit rating agency registered with the ESMA and selected by the manager of an MMF if suited to the specific investment portfolio of the MMF.
kjer je ustrezno, analiza bonitetnih ocen ali obeta bonitetnih ocen, ki jih je izdajatelju instrumenta pripisala bonitetna agencija, ki je registrirana pri ESMA in jo je izbral upravitelj sklada denarnega trga, če ustreza posebnemu naložbenemu portfelju tega sklada.
Criteria for establishing qualitative credit risk indicators in realtion to the issuer of the instrument, as referred to in Article 20(2)(b) of Regulation (EU) 2017/1131
Merila za vzpostavitev kvalitativnih kazalnikov kreditnega tveganja v zvezi z izdajateljem instrumenta iz člena 20(2)(b) Uredbe (EU) 2017/1131
Insofar as is possible, managers of MMFs shall assess the following qualitative credit risk criteria for an issuer of an instrument:
Upravitelji skladov denarnega trga po možnosti ocenijo naslednja kvalitativna merila kreditnega tveganja za izdajatelja instrumenta:
the financial situation of the issuer, or, where applicable, of the guarantor;
finančni položaj izdajatelja ali poroka, kjer je ustrezno;
the sources of liquidity of the issuer, or, where applicable, of the guarantor;
vire likvidnosti izdajatelja ali poroka, kjer je ustrezno;
the ability of the issuer to react to future market-wide or issuer-specific events, including the ability to repay debt in a highly adverse situation;
zmožnost izdajatelja za odzivanje na prihodnje dogodke na ravni trga ali dogodke, značilne za posameznega izdajatelja, vključno z zmožnostjo odplačati dolgove v zelo neugodnih razmerah;
the strength of the issuer's industry within the economy relative to economic trends and the issuer's competitive positon in its industry.
moč panoge izdajatelja znotraj gospodarstva glede na gospodarska gibanja in konkurenčni položaj izdajatelja v njegovi panogi.
Managers of MMFs may override the output of an internal credit quality assessment methodology only in exceptional circumstances, including stressed market conditions, and where there is an objective reason for doing so.
Upravitelji skladov denarnega trga lahko rezultat uporabe metodologije notranjega ocenjevanja kreditne kakovosti razveljavijo samo v izjemnih okoliščinah, tudi v izjemnih tržnih razmerah, in kadar obstaja objektiven razlog za to.
Managers of MMFs which override the output of an internal credit quality assessment methodology shall document that decision.
Upravitelji skladov denarnega trga, ki razveljavijo rezultat uporabe metodologije notranjega ocenjevanja kreditne kakovosti, to odločitev dokumentirajo.
As part of the documenting process referred to in paragraph 1, managers of MMFs shall specify the person who is responsible for the decision as well as the objective reason for taking that decision.
Upravitelji skladov denarnega trga v okviru postopka dokumentiranja iz odstavka 1 navedejo osebo, odgovorno za odločitev, in objektivni razlog za sprejetje te odločitve.
Material change as referred to in Article 19(4)(d) of Regulation (EU) 2017/1131
Pomembna sprememba iz člena 19(4)(d) Uredbe (EU) 2017/1131
There will be a material change as referred to in Article 19(4)(d) of Regulation (EU) 2017/1131 whenever:
Do pomembne spremembe iz člena 19(4)(d) pride, kadar:
there is a material change with respect to any of the following:
se pomembno spremeni kateri koli od naslednjih elementov:
default statistics relating to the issuer or instrument;
statistični podatki o neplačilih v zvezi z izdajateljem ali instrumentom;
financial indices relating to the geographic location, industry sector or asset class of the issuer or instrument;
finančni indeksi v zvezi z geografsko lokacijo, panogo ali razredom sredstev izdajatelja ali instrumenta;
analysis of underlying assets, in particular for structured instruments;
analiza osnovnih sredstev, zlasti za strukturirane instrumente;
analysis of the relevant market(s), including their volume and liquidity;
analiza relevantnih trgov, vključno z njihovim obsegom in likvidnostjo;
analysis of the structural aspects of the relevant instruments;
analiza strukturnih vidikov relevantnih instrumentov;
securities-related research;
raziskave glede vrednostnih papirjev;
financial situation of the issuer;
finančni položaj izdajatelja;
sources of liquidity of the issuer;
viri likvidnosti izdajatelja;
ability of the issuer to react to future market-wide or issuer-specific events, including the ability to repay debt in a highly adverse situation;
zmožnost izdajatelja za odzivanje na prihodnje dogodke na ravni trga ali dogodke, značilne za posameznega izdajatelja, vključno z zmožnostjo odplačati dolgove v zelo neugodnih razmerah;
strength of the issuer's industry within the economy relative to economic trends and the issuer's competitive positon in its industry;
moč panoge izdajatelja znotraj gospodarstva glede na gospodarska gibanja in konkurenčni položaj izdajatelja v njegovi panogi;
analysis of the credit ratings or rating outlook given to the issuer or instrument by a credit rating agency or agencies selected by the manager of the MMF as being suited to the specific investment portfolio of the MMF.
analiza bonitetnih ocen ali obeta bonitetnih ocen, ki jih je izdajatelju ali instrumentu pripisala bonitetna agencija ali bonitetne agencije, ki jih je upravitelj sklada denarnega trga izbral kot ustrezne za posebni naložbeni portfelj tega sklada;
a money market instrument, securitisation or ABCP is downgraded below the two highest short-term credit ratings provided by any credit rating agency regulated and certified in accordance with Regulation (EC) No 1060/2009 of the European Parliament and of the Council.
se ocena instrumenta denarnega trga, listinjenja ali komercialnega zapisa s premoženjskim kritjem zniža na raven pod dvema najvišjima kratkoročnima bonitetnima ocenama, ki ju je izdala katera koli bonitetna agencija, regulirana in certificirana v skladu z Uredbo (ES) št. 1060/2009 Evropskega parlamenta in Sveta.
Managers of MMFs shall assess the material change in the criteria referred to in paragraph 1(a) by considering risk factors and the results of the stress test scenarios referred to in Article 28 of Regulation (EU) 2017/1131.
Upravitelji skladov denarnega trga ocenijo pomembno spremembo meril iz odstavka 1(a), tako da upoštevajo dejavnike tveganja in rezultate scenarijev za teste izjemnih situacij iz člena 28 Uredbe (EU) 2017/1131.
For the purpose of paragraph 1(b), managers of MMFs shall establish an internal procedure for the selection of credit rating agencies suited to the specific investment portfolio of the MMF concerned and for the determination of the frequency with which the MMF shall monitor the ratings of those agencies.
Upravitelji skladov denarnega trga za namene odstavka 1(b) vzpostavijo notranji postopek za izbor bonitetnih agencij, ki ustrezajo posebnemu naložbenemu portfelju zadevnega sklada denarnega trga, in za določitev, kako pogosto sklad denarnega trga spremlja bonitetne ocene teh agencij.
Managers of MMFs shall take into account a downgrading as referred to in paragraph 1(b) and thereupon carry out their own assessment according to their internal credit quality assessment methodology.
Upravitelji skladov denarnega trga upoštevajo znižanje bonitetne ocene iz odstavka 1(b) in nato sami izvedejo oceno v skladu s svojo metodologijo notranjega ocenjevanja kreditne kakovosti.
The revision of the internal credit quality assessment methodology shall constitute a material change as referred to in Article 19(4)(d) of Regulation (EU) 2017/1131, except if managers of MMFs can substantiate that the change is not material.
Sprememba metodologije notranjega ocenjevanja kreditne kakovosti pomeni pomembno spremembo iz člena 19(4)(d) Uredbe (EU) 2017/1131, razen če lahko upravitelji skladov denarnega trga utemeljijo, da ta sprememba ni pomembna.
Quantitative and qualitative credit quality requirements for assets referred to in Article 15(6)(a) of Regulation (EU) 2017/1131
Kvantitativne in kvalitativne zahteve glede kreditne kakovosti za sredstva iz člena 15(6)(a) Uredbe (EU) 2017/1131
Managers of MMFs shall apply Articles 3 to 8 of this Regulation when assessing the credit quality of the liquid transferable securities or money market instruments referred to in Article 15(6)(a) of Regulation (EU) 2017/1131.
Upravitelji skladov denarnega trga pri ocenjevanju kreditne kakovosti likvidnih prenosljivih vrednostnih papirjev ali instrumentov denarnega trga iz člena 15(6)(a) Uredbe (EU) 2017/1131 uporabljajo člene od 3 do 8 te uredbe.
It shall apply from 21 July 2018, with the exception of Article 1 which shall apply from 1 January 2019.
Uporablja se od 21. julija 2018, razen člena 1, ki se uporablja od 1. januarja 2019.
Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017 laying down a general framework for securitisation and creating a specific framework for simple, transparent and standardised securitisation, and amending Directives 2009/65/EC, 2009/138/EC and 2011/61/EU and Regulations (EC) No 1060/2009 and (EU) No 648/2012 (OJ L 347, 28.12.2017, p. 35).
Uredba (EU) 2017/2402 Evropskega parlamenta in Sveta z dne 12. decembra 2017 o določitvi splošnega okvira za listinjenje in o vzpostavitvi posebnega okvira za enostavno, pregledno in standardizirano listinjenje ter o spremembah direktiv 2009/65/ES, 2009/138/ES in 2011/61/EU ter uredb (ES) št. 1060/2009 in (EU) št. 648/2012 (UL L 347, 28.12.2017, str. 35).
Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017 laying down a general framework for securitisation and creating a specific framework for simple, transparent and standardised securitisation, and amending Directives 2009/65/EC, 2009/138/EC and 2011/61/EU and Regulations (EC) No 1060/2009 and (EU) No 648/2012 (OJ L 347, 28.12.2017, p. 35)’.
Uredba (EU) 2017/2402 Evropskega parlamenta in Sveta z dne 12. decembra 2017 o določitvi splošnega okvira za listinjenje in o vzpostavitvi posebnega okvira za enostavno, pregledno in standardizirano listinjenje ter o spremembah direktiv 2009/65/ES, 2009/138/ES in 2011/61/EU ter uredb (ES) št. 1060/2009 in (EU) št. 648/2012 (UL L 347, 28.12.2017, str. 35).“
Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (OJ L 173, 12.6.2014, p. 349).
Direktiva 2014/65/EU Evropskega parlamenta in Sveta z dne 15. maja 2014 o trgih finančnih instrumentov ter spremembi Direktive 2002/92/ES in Direktive 2011/61/EU (UL L 173, 12.6.2014, str. 349).
Directive 2009/138/EC of the European Parliament and of the Council of 25 November 2009 on the taking-up and pursuit of the business of Insurance and Reinsurance (Solvency II) (OJ L 335, 17.12.2009, p. 1).
Direktiva 2009/138/ES Evropskega parlamenta in Sveta z dne 25. novembra 2009 o začetku opravljanja in opravljanju dejavnosti zavarovanja in pozavarovanja (Solventnost II) (UL L 335, 17.12.2009, str. 1).
Commission Implementing Regulation (EU) 2018/991
Izvedbena uredba Komisije (EU) 2018/991
authorising the placing on the market of hen egg white lysozyme hydrolysate as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) 2017/2470
o odobritvi dajanja na trg hidrolizata lizocima iz kokošjega jajčnega beljaka kot novo živilo v skladu z Uredbo (EU) 2015/2283 Evropskega parlamenta in Sveta ter spremembi Izvedbene uredbe Komisije (EU) 2017/2470
Having regard to Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 and Commission Regulation (EC) No 1852/2001, and in particular Article 12 thereof,
ob upoštevanju Uredbe (EU) 2015/2283 Evropskega parlamenta in Sveta z dne 25. novembra 2015 o novih živilih, spremembi Uredbe (EU) št. 1169/2011 Evropskega parlamenta in Sveta in razveljavitvi Uredbe (ES) št. 258/97 ter Uredbe Komisije (ES) št. 1852/2001 in zlasti člena 12 Uredbe,
Pursuant to Article 12 of Regulation (EU) 2015/2283, the Commission is to decide on the authorisation and on the placing on the Union market of a novel food and updating the Union list.
Na podlagi člena 12 Uredbe (EU) 2015/2283 Komisija odloči o odobritvi in o dajanju novega živila na trg v Uniji in posodobitvi seznama Unije.
On 31 August 2016, the company DSM Nutritional Products Ltd, United Kingdom, made a request to the competent authority of Ireland to place hen egg white lysozyme hydrolysate on the Union market as a novel food within the meaning of point (e) of Article 1(2) of Regulation (EC) No 258/97 of the European Parliament and of the Council.
Podjetje DSM Nutritional Products Ltd. iz Združenega kraljestva je 31. avgusta 2016 pri pristojnem organu Irske vložilo zahtevo za dajanje na trg v Uniji hidrolizata lizocima iz kokošjega jajčnega beljaka kot nove živilske sestavine v smislu točke (e) člena 1(2) Uredbe (ES) št. 258/97 Evropskega parlamenta in Sveta.
The application requests for hen egg white lysozyme hydrolysate to be used in food supplements and other food categories, in particular, in non-alcoholic beverages.
V vlogi zahteva odobritev uporabe hidrolizata lizocima iz kokošjega jajčnega beljaka v prehranskih dopolnilih in drugih kategorijah živil, zlasti v brezalkoholnih pijačah.
Pursuant to Article 35(1) of Regulation (EU) 2015/2283, any request for placing a novel food on the market within the Union submitted to a Member State in accordance with Article 4 of Regulation (EC) No 258/97 and for which the final decision has not been taken before 1 January 2018, shall be treated as an application submitted under Regulation (EU) 2015/2283.
Na podlagi člena 35(1) Uredbe (EU) 2015/2283 se kakršna koli zahteva za dajanje novega živila na trg v Uniji, ki jo predloži država članica v skladu s členom 4 Uredbe (ES) št. 258/97 ter za katero končna odločitev ni bila sprejeta pred 1. januarjem 2018, obravnava kot vloga na podlagi Uredbe (EU) 2015/2283.
While the request for placing hen egg white lysozyme hydrolysate on the market as a novel food within the Union was submitted to a Member State in accordance with Article 4 of Regulation (EC) No 258/97, the application also meets the requirements laid down in Regulation (EU) 2015/2283.
Zahteva za dajanje na trg v Uniji hidrolizata lizocima iz kokošjega jajčnega beljaka kot novega živila je bila državi članici predložena v skladu s členom 4 Uredbe (ES) št. 258/97, vendar izpolnjuje tudi zahteve iz Uredbe (EU) 2015/2283.
On 12 May 2017, the competent authority of Ireland issued its initial assessment report.
Pristojni organ Irske je 12. maja 2017 izdal poročilo o začetni presoji.
In that report it came to the conclusion that hen egg white lysozyme hydrolysate meets the criteria for novel food set out in Article 3(1) of Regulation (EC) No 258/97.
V navedenem poročilu ugotavlja, da hidrolizat lizocima iz kokošjega jajčnega beljaka izpolnjuje merila za novo živilo iz člena 3(1) Uredbe (ES) št. 258/97.
On 31 May 2017, the Commission forwarded the initial assessment report to the other Member States.
Komisija je 31. maja 2017 poročilo o začetni presoji poslala drugim državam članicam.
Reasoned objections were raised by the other Member States within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97 with regard to insufficient information on intended uses and exposure assessment, toxicological data, product specification and production process.
Te so v roku 60 dni, ki je določen v prvem pododstavku člena 6(4) Uredbe (ES) št. 258/97, vložile upravičene ugovore zaradi nezadostnih informacij o predvidenih uporabah in oceni izpostavljenosti, toksikoloških podatkih, specifikaciji proizvoda in proizvodnem postopku.
In view of the objections raised by the other Member States, in particular the insufficient exposure assessment on the potential combined intake from all possible proposed uses the applicant modified the request with regard to the food categories by limiting the use of the novel food only to food supplements.
Vložnik je na podlagi ugovorov, ki so jih vložile druge države članice, zlasti v zvezi z nezadostno oceno izpostavljenosti pri potencialnem kombiniranem vnosu iz vseh možnih predlaganih uporab, spremenil zahtevo glede kategorij živil, tako da je omejil uporabo novega živila izključno na prehranska dopolnila.
The changes in the proposed uses of the novel food and additional explanations by the applicant alleviated the concerns regarding compliance with Article 7 of Regulation (EU) 2015/2283 to the satisfaction of the Member States and the Commission.
S spremembami predlaganih uporab novega živila in dodatnimi pojasnili vložnika je bila zaskrbljenost držav članic in Komisije v zvezi s skladnostjo s členom 7 Uredbe (EU) 2015/2283 odpravljena.
Those explanations give sufficient grounds to establish that hen egg white lysozyme hydrolysate in the proposed uses and use levels when used as an ingredient in food supplements, complies with Article 12(1) of Regulation (EU) 2015/2283.
V navedenih razlagah je dovolj dokazov, da so predlagane uporabe in ravni uporabe hidrolizata lizocima iz kokošjega jajčnega beljaka, če se uporablja kot sestavina prehranskih dopolnil, skladne z merili iz člena 12(1) Uredbe (EU) 2015/2283.
The use of hen egg white lysozyme hydrolysate should be authorised without prejudice to that Directive.
Uporabo hidrolizata lizocima iz kokošjega jajčnega beljaka bi bilo treba odobriti brez poseganja v navedeno direktivo.
Hen egg white lysozyme hydrolysate as specified in the Annex to this Regulation shall be included in the Union list of authorised novel foods as provided for in Article 8 of Regulation (EU) 2015/2283.
Hidrolizat lizocima iz kokošjega jajčnega beljaka, kakor je opredeljen v Prilogi k tej uredbi, se vključi na seznam Unije z odobrenimi novimi živili, kakor je določeno v členu 8 Uredbe (EU) 2015/2283.
Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ L 183, 12.7.2002, p. 51).
Direktiva 2002/46/ES Evropskega parlamenta in Sveta z dne 10. junija 2002 o približevanju zakonodaj držav članic o prehranskih dopolnilih (UL L 183, 12.7.2002, str. 51).
The Annex to Implementing Regulation (EU) 2017/2470 is amended as follows:
Priloga k Izvedbeni uredbi (EU) 2017/2470 se spremeni:
The following entry is inserted in Table 1 (Authorised novel foods) in alphabetical order:
V tabelo 1 (Odobrena nova živila) se po abecednem vrstnem redu vstavi naslednji vnos:
‘Authorised novel food
„Odobreno novo živilo
Conditions under which the novel food may be used
Pogoji za uporabo novih živil
Additional specific labelling requirements
Dodatne posebne zahteve za označevanje
Hen egg white lysozyme hydrolysate
Hidrolizat lizocima iz kokošjega jajčnega beljaka
Specified food category
Določena kategorija živil
Maximum levels
Najvišje dovoljene ravni
The designation of the novel food on the labelling of food supplements containing it shall be “Hen egg white lysozyme hydrolysate”.’
Poimenovanje novega živila pri označevanju prehranskih dopolnil, ki ga vsebujejo, je ‚hidrolizat lizocima iz kokošjega jajčnega beljaka‘.“
Food supplements as defined in Directive 2002/46/EC intended for adult population
Prehranska dopolnila, kot so opredeljena v Direktivi 2002/46/ES, za odraslo populacijo.
The following entry is inserted in Table 2 (Specifications) in alphabetical order:
V tabelo 2 (Specifikacije) se po abecednem vrstnem redu vstavi naslednji vnos:
‘Authorised Novel Food
„Odobreno novo živilo
Specification
Specifikacije
Description/Definition:
Opis/opredelitev:
Hen egg white lysozyme hydrolysate is obtained from hen egg white lysozyme by an enzymatic process, using subtilisin from Bacillus licheniformis.
Hidrolizat lizocima iz kokošjega jajčnega beljaka se pridobi iz lizocima kokošjega jajčnega beljaka z encimskim postopkom, pri katerem se uporabi subtilizin iz Bacillus licheniformis.
The product is a white to light yellow powder.
Proizvod je bel do svetlo rumen prah.
Protein (TN (*) × 5,30): 80-90 %
beljakovine (TN (*) × 5,30): 80–90 %
Tryptophan: 5-7 %
triptofan: 5–7 %
Ratio Tryptophan/LNAA (**): 0,18-0,25
razmerje triptofan/LNAA (**): 0,18–0,25
Degree of hydrolysis: 19-25 %
stopnja hidrolize: 19–25 %
Moisture: < 5 %
vlaga: < 5 %
Ash: < 10 %
pepel: < 10 %
Sodium: < 6 %
natrij: < 6 %
Heavy metals:
Težke kovine:
Arsenic: < 1 ppm
arzen: < 1 ppm
Lead: < 1 ppm
svinec: < 1 ppm
Cadmium: < 0,5 ppm
kadmij: < 0,5 ppm
Mercury: < 0,1 ppm
živo srebro: < 0,1 ppm
Total aerobic count: < 103 CFU/g
skupno število aerobnih bakterij: < 103 CFU/g
Total combined yeasts/moulds count: < 102 CFU/g
skupno število kvasovk/plesni: < 102 CFU/g
Enterobacteria: < 10 CFU/g
enterobakterije: < 10 CFU/g
Salmonella spp: Absence in 25 g
Salmonella spp: odsotnost v 25 g
Escherichia coli: Absence in 10 g
Escherichia coli: odsotnost v 10 g
Staphylococcus aureus: Absence in 10 g
Staphylococcus aureus: odsotnost v 10 g
Pseudomonas aeruginosa: Absence in 10 g
Pseudomonas aeruginosa: odsotnost v 10 g
TN: total nitrogen
TN: skupni dušik
LNAA: large neutral amino acids’
LNAA: velike nevtralne aminokisline“
Commission Implementing Regulation (EU) 2018/995
Izvedbena uredba Komisije (EU) 2018/995
Having regard to Commission Implementing Regulation (EU) 2016/1240 of 18 May 2016 laying down rules for the application of Regulation (EU) No 1308/2013 of the European Parliament and of the Council with regard to public intervention and aid for private storage, and in particular Article 28 thereof,
ob upoštevanju Izvedbene uredbe Komisije (EU) 2016/1240 z dne 18. maja 2016 o pravilih za uporabo Uredbe (EU) št. 1308/2013 Evropskega parlamenta in Sveta glede javne intervencije in pomoči za zasebno skladiščenje ter zlasti člena 28 Uredbe,
Commission Implementing Regulation (EU) 2016/2080 has opened the sale of skimmed milk powder by a tendering procedure.
Izvedbena uredba Komisije (EU) 2016/2080 je začela prodajo posnetega mleka v prahu z razpisnim postopkom.
It provided initially for two partial invitations to tender per month, except for August and December.
Na začetku je določala dva delna javna razpisa na mesec, razen za avgust in december.